Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:43:41.858Z.
Calculation as of: 2026-10-06T20:43:41.858Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 148236961db35e193d1d700acaf87b22991c3a1a7f0bfa22e817431605aef681
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Zhengye Biotechnology Holding Limited
Market Cap
$52.60M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.99M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$53.70M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.19M
EV/Sales Ratio
N/A
TTM Avg
828.86x
3Y Avg
1129.78x
5Y Avg
739.58x
Market Cap
$54.14M
EV/Sales Ratio
10.83x
TTM Avg
51.21x
3Y Avg
45.57x
5Y Avg
60.27x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Limited (ZYBT) | $52.60M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | 3.64x | 2.57x | 1.84x | 3.18x |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A | 46.89x | 17.85x | 13.82x |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | 828.86x | 1129.78x | 739.58x |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | 10.83x | 51.21x | 45.57x | 60.27x |
| biote Corp. (BTMD)vs › | $50.28M | 0.91x | 0.87x | 1.10x | 0.92x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
